MedTrace Logo

Cerebrospinal Fluid Biomarkers for Brain Tumors

NCT04692324 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2026-04-22

No results posted yet for this study

Summary

This study examines cerebrospinal biomarkers in patients with brain tumors. A biomarker is a measurable indicator of the severity or presence of your disease state. Collecting and storing samples of cerebrospinal fluid from patients with brain tumors to study in the laboratory may help doctors develop new strategies to better diagnose, monitor, and treat brain tumors.

Conditions

  • Central Nervous System Neoplasm

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of CSF samples

OTHER

Electronic Health Record Review

Review of medical records

Sponsors & Collaborators

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Terry C. Burns, MD, PhD · Mayo Clinic in Rochester

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-14
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04692324 on ClinicalTrials.gov